破傷風:治療薬開発パイプライン分析

◆英語タイトル:Tetanus - Pipeline Review, H2 2017
◆商品コード:GMDHC9736IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2017年9月19日
◆ページ数:71
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥660,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における破傷風の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・破傷風の概要
・破傷風治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・破傷風パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・破傷風治療薬開発に取り組んでいる企業:企業別製品パイプライン
・破傷風治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Tetanus – Pipeline Review, H2 2017

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Tetanus – Pipeline Review, H2 2017, provides an overview of the Tetanus (Infectious Disease) pipeline landscape.

Tetanus is a serious illness caused by Clostridium bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. The predisposing factors include burns, surgical wounds, ear infections, swelling around the injury and infected foot ulcers. Treatment includes antibiotics, sedatives and beta blockers.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Tetanus – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Tetanus (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tetanus (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tetanus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 1, 9, 4, 5, 1 and 8 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 2 molecules, respectively.

Tetanus (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Tetanus (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Tetanus (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Tetanus (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Tetanus (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Tetanus (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tetanus (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tetanus (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tetanus – Overview
Tetanus – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Tetanus – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tetanus – Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co Ltd
Bharat Biotech International Ltd
Biological E Ltd
Cadila Healthcare Ltd
Daiichi Sankyo Company Ltd
GlaxoSmithKline Plc
Green Cross Corp
Indian Immunologicals Ltd
Kaketsuken
LG Chem, Ltd.
Sanofi
Sanofi Pasteur SA
Serum Institute of India Ltd
Shantha Biotechnics Pvt Ltd
Tetanus – Drug Profiles
(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine 1 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine 2 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (whole cell) + tetanus) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (whole-cell) + tetanus) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus + pertussis (acellular)) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BK-1310 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DTaP-IPV-HB-PRPT – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GC-3111A – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KD-370 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBVD – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Tetanus – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tetanus vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tetanus vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tetanus vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VN-0105 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tetanus – Dormant Projects
Tetanus – Discontinued Products
Tetanus – Product Development Milestones
Featured News & Press Releases
Mar 17, 2015: Sanofi: Shantha Will Provide Up To 37 Million Doses Of Shan5
Nov 24, 2014: CanSinotech submitted CTA of “Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed” to CFDA
Nov 10, 2014: Shantha’s Pentavalent Pediatric Vaccine launched in India
May 05, 2014: Shantha’s Pentavalent Pediatric Vaccine prequalified by World Health Organization
May 11, 2011: Sanofi Pasteur Launches Pentaxim In China
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Tetanus, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Tetanus - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2017
Tetanus - Pipeline by Bharat Biotech International Ltd, H2 2017
Tetanus - Pipeline by Biological E Ltd, H2 2017
Tetanus - Pipeline by Cadila Healthcare Ltd, H2 2017
Tetanus - Pipeline by Daiichi Sankyo Company Ltd, H2 2017
Tetanus - Pipeline by GlaxoSmithKline Plc, H2 2017
Tetanus - Pipeline by Green Cross Corp, H2 2017
Tetanus - Pipeline by Indian Immunologicals Ltd, H2 2017
Tetanus - Pipeline by Kaketsuken, H2 2017
Tetanus - Pipeline by LG Chem, Ltd., H2 2017
Tetanus - Pipeline by Sanofi, H2 2017
Tetanus - Pipeline by Sanofi Pasteur SA, H2 2017
Tetanus - Pipeline by Serum Institute of India Ltd, H2 2017
Tetanus - Pipeline by Shantha Biotechnics Pvt Ltd, H2 2017
Tetanus - Dormant Projects, H2 2017
Tetanus - Dormant Projects, H2 2017 (Contd..1), H2 2017
Tetanus - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Tetanus, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

【レポートのキーワード】

破傷風

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 破傷風:治療薬開発パイプライン分析(Tetanus - Pipeline Review, H2 2017)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆